Daiichi Sankyo $4568.T
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS36
PHASE 3 / 2-320
RECRUITING21
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO43%
Delay Index: of 30 active trials registered more than a year ago, 13 have moved their primary completion (readout) date by more than 6 months since first registration (median +1.6 months). See all sponsors →
Open Daiichi Sankyo on the live radar map → 📅 $4568.T readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Patritumab Deruxtecan (Fixed dose) NCT04619004 |
P2 | Active, not recruiting | Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | 277 | 2022-11-21 (-12 mo) |
| Valemetostat Tosylate NCT04703192 |
P2 | Active, not recruiting | Relapsed/Refractory Peripheral T-Cell Lymphoma; Adult T Cell Leukemia/Lymphoma | 155 | 2023-05-10 (-5 mo) |
| DS-1062a NCT04656652 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 605 | 2024-05-10 (+18 mo) |
| Patritumab Deruxtecan NCT05338970 |
P3 | Active, not recruiting | Nonsquamous Non-small Cell Lung Cancer; EGFR L858R | 586 | 2024-05-31 (-3 mo) |
| IDeate-Lung01 NCT05280470 |
P2 | Active, not recruiting | Extensive-stage Small-cell Lung Cancer | 187 | 2025-03-03 (+17 mo) |
| DS-8201a NCT04622319 |
P3 | Active, not recruiting | HER2-Positive Primary Breast Cancer; Residual Invasive Breast Cancer | 1600 | 2025-07-02 (-6 mo) |
| Trastuzumab deruxtecan NCT04704934 |
P3 | Active, not recruiting | Gastric Cancer, Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | 490 | 2026-08-31 (+29 mo) |
| Ifinatamab deruxtecan (I-DXd) NCT04145622 |
P1/2 | Active, not recruiting | Advanced Solid Tumor; Malignant Solid Tumor | 247 | 2027-04-30 (+51 mo) |
| Quizartinib NCT03793478 |
P1/2 | Active, not recruiting | Acute Myeloid Leukemia | 65 | 2027-05-01 |
| Ifinatamab deruxtecan NCT06362252 |
P1/2 | Recruiting | Extensive Stage-small Cell Lung Cancer | 123 | 2027-07-20 (+8 mo) |
| Trastuzumab Deruxtecan NCT05950945 |
P3 | Recruiting | Breast Cancer | 250 | 2027-10-01 |
| IDeate-Lung02 NCT06203210 |
P3 | Recruiting | Small Cell Lung Cancer | 540 | 2028-01-30 (+18 mo) |
| T-DXd NCT06174987 |
P3 | Recruiting | Advanced Cancer; Metastatic Cancer | 75 | 2028-02-17 (+18 mo) |
| R-DXd NCT06161025 |
P2/3 | Recruiting | Solid Cancer | 860 | 2028-02-29 (+2 mo) |
| valemetostat tosylate NCT06644768 |
P1/2 | Active, not recruiting | Non-small Cell Lung Cancer; Lung Cancer | 137 | 2028-03-30 |
| Trastuzumab Deruxtecan NCT06731478 |
P3 | Recruiting | Gastric Cancer; Gastroesophageal Junction Cancer | 726 | 2028-06-01 |
| Ifinatamab deruxtecan NCT06644781 |
P3 | Recruiting | Esophageal Squamous Cell Carcinoma | 510 | 2028-06-01 (-12 mo) |
| Bempedoic acid NCT07474649 |
P3 | Recruiting | Coronary Atherosclerosis; Mixed Dyslipidemia | 103 | 2028-06-01 |
| Quizartinib High Dose NCT06824168 |
P2 | Recruiting | Acute Myeloid Leukemia; Leukemia | 130 | 2028-06-06 |
| Ifinatamab deruxtecan NCT06330064 |
P1/2 | Recruiting | Recurrent or Metastatic Solid Tumors | 680 | 2028-07-25 (+20 mo) |
| DS-3939a NCT05875168 |
P1/2 | Recruiting | Advanced Solid Tumor; Metastatic Solid Tumor | 590 | 2028-08-11 (+29 mo) |
| DO-01 NCT06819007 |
P3 | Recruiting | Ovarian Cancer | 582 | 2028-11-01 |
| Datopotamab Deruxtecan NCT05555732 |
P3 | Active, not recruiting | Metastatic Non Small Cell Lung Cancer | 1233 | 2029-05-11 (+21 mo) |
| Dato-DXd NCT07129993 |
P2/3 | Recruiting | Urothelial Cancer; Bladder Cancer | 630 | 2029-06-01 (-8 mo) |
| R-DXd NCT07791732 |
P3 | Not yet recruiting | Fallopian Tube Cancer; Primary Peritoneal Cancer | 600 | 2029-07-01 |
| Dato-DXd NCT07890714 |
P1/2 | Recruiting | Urothelial Cancer; Non-small Cell Lung Cancer | 268 | 2029-09-30 |
| Raludotatug deruxtecan NCT06660654 |
P2 | Active, not recruiting | Advanced Solid Tumor; Metastatic Solid Tumors | 335 | 2029-12-30 (+27 mo) |
| Trastuzumab Deruxtecan NCT07022483 |
P3 | Recruiting | Endometrial Cancer | 710 | 2030-02-26 (-25 mo) |
| TROPION-Lung08 NCT05215340 |
P3 | Active, not recruiting | Metastatic Non Small Cell Lung Cancer | 740 | 2030-03-04 (+45 mo) |
| DESTINY-Lung06 NCT06899126 |
P3 | Recruiting | Non-small Cell Lung Cancer | 686 | 2030-04-24 (+2 mo) |
| QuANTUM-WILD NCT06578247 |
P3 | Active, not recruiting | Leukemia | 700 | 2030-06-26 |
| DB-Guide NCT07683754 |
P3 | Recruiting | Advanced Breast Cancer; Metastatic Breast Cancer | 200 | 2030-07-04 |
| DS-3939a NCT07739966 |
P1/2 | Recruiting | Solid Tumor; Locally Advanced Non-Small Cell Lung Cancer | 400 | 2030-07-31 |
| HER3-DXd NCT06172478 |
P2 | Recruiting | Advanced Solid Tumor; Melanoma | 890 | 2030-11-19 (+65 mo) |
| DS3790a NCT07220616 |
P1/2 | Recruiting | Hematological Malignancies; B-cell Non-Hodgkin Lymphoma | 420 | 2030-11-30 |
| Patritumab deruxtecan NCT07701941 |
P1/2 | Recruiting | Hormone Receptor Positive; HER2-low or HER2-ultralow | 220 | 2031-01-01 |